Hutchison Rob W, Tucker William F, Kim Sunghyun, Gilder Richard
Presbyterian Hospital of Dallas, 8200 Walnut Hill Lane, Pharmacy Department, Dallas, TX 75231, USA.
Am J Hosp Palliat Care. 2006 Aug-Sep;23(4):328-31. doi: 10.1177/1049909106290244.
Assessment of pain intensity using a standard self-reported pain score is standard practice in most institutions. These instruments require the cognitive ability to process the pain intensity into a numeric or descriptive value. Many institutions are considering adopting an assessment tool for cognitive impairment. The purpose of this study is to evaluate a clinician-administered assessment tool, PAINAD, in patients with cognitive impairment. Opioid consumption and frequency of documented unknown pain were collected in 2 cognitive impaired groups. In the control group, a self-reporting pain intensity tool was used, and in a second group, the PAINAD was used. Opioid use was significantly higher (P = .003) and the rates of reported unknown pain were significantly lower (P < .01) in the group using the PAINAD instrument compared to the control group of patients with cognitive impairment. There were no noted differences in opioid-induced adverse reactions in either group.
在大多数机构中,使用标准的自我报告疼痛评分来评估疼痛强度是标准做法。这些工具需要具备将疼痛强度转化为数字或描述性值的认知能力。许多机构正在考虑采用一种针对认知障碍的评估工具。本研究的目的是评估一种由临床医生实施的评估工具——疼痛评估指标(PAINAD),用于认知障碍患者。在两个认知障碍组中收集了阿片类药物的使用情况和记录的不明疼痛频率。在对照组中,使用自我报告疼痛强度工具,在另一组中,使用PAINAD。与认知障碍患者的对照组相比,使用PAINAD工具的组中阿片类药物的使用显著更高(P = 0.003),报告的不明疼痛发生率显著更低(P < 0.01)。两组中阿片类药物引起的不良反应均无明显差异。